<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02195440</url>
  </required_header>
  <id_info>
    <org_study_id>PRI-724-1101</org_study_id>
    <secondary_id>000014395</secondary_id>
    <nct_id>NCT02195440</nct_id>
  </id_info>
  <brief_title>An Open Label, Single Arm, Dose Escalation Phase 1 Trial of PRI-724 in Patients With HCV-induced Cirrhosis</brief_title>
  <official_title>An Open Label, Single Arm, Dose Escalation Phase 1 Trial of PRI-724 in Patients With HCV-induced Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Komagome Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prism Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Komagome Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and tolerability of PRI-724 in
      patients with HCV-induced cirrhosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">March 31, 2017</completion_date>
  <primary_completion_date type="Actual">March 31, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events and adverse drug reactions (including subjective symptoms and abnormal laboratory values)</measure>
    <time_frame>12 weeks after the initiation of PRI-724 administration</time_frame>
    <description>Items and ratio%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Child-Pugh Score</measure>
    <time_frame>12 weeks after the initiation of PRI-724 administration</time_frame>
    <description>Changes of score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver biopsy: Histology Activity Index (HAI)</measure>
    <time_frame>12 weeks after the initiation of PRI-724 administration</time_frame>
    <description>Changes of index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum albumin level</measure>
    <time_frame>12 weeks after the initiation of PRI-724 administration</time_frame>
    <description>Changes of level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum fibrosis marker level(s)</measure>
    <time_frame>12 weeks after the initiation of PRI-724 administration</time_frame>
    <description>Changes of level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ascitic fluid level</measure>
    <time_frame>12 weeks after the initiation of PRI-724 administration</time_frame>
    <description>Changes of level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement rate of lower leg edema</measure>
    <time_frame>12 weeks after the initiation of PRI-724 administration</time_frame>
    <description>Changes of rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Area under the plasma concentration versus time curve (AUCinf) of PRI-724 through analysis of blood samples</measure>
    <time_frame>Days 1-2 for preinfusion, 0.5, 1.0, 2.0, 4.0, and 24h; Day 7-8 for prestopping, 0.5, 1.0, 2.0, 4.0, and 24h</time_frame>
    <description>Comparison of AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Steady State Plasma Concentration (Css) of PRI-724 through analysis of blood samples</measure>
    <time_frame>Days 1-2 for preinfusion, 0.5, 1.0, 2.0, 4.0, and 24h; Day 7-8 for prestopping, 0.5, 1.0, 2.0, 4.0, and 24h</time_frame>
    <description>Comparison of Css</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Hepatitis C Virus-infected Cirrhosis</condition>
  <arm_group>
    <arm_group_label>PRI-724</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRI-724</intervention_name>
    <description>10 - 160 mg/m2, 7 days CIV (in the vein) with 7 days rest per one cycle. Number of Cycles: 6.</description>
    <arm_group_label>PRI-724</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Presence of cirrhosis due to hepatitis C virus. 1) Serum HCV-RNA test positive 2)
             Definitive diagnosis of cirrhosis established by liver biopsy (HAI score: Grade IV-D).

          2. Child-Pugh Class A or B at the time of informed consent, with no likelihood of
             improvement with existing medical treatment.

          3. Performance Status: 0 - 2.

          4. Between =&gt;20 and &lt;75 years of age at the time of providing written consent.

          5. Having provided voluntary written consent for participation in this study.

          6. Esophageal and gastric varices are well controlled

        Exclusion Criteria:

          1. Patients with cirrhosis due to causes other than hepatitis C virus; or patients with
             cirrhosis due to unknown causes.

          2. Patients with a history of primary liver cancer or a complication thereof.

          3. Patients with a complication of malignant tumor or a history thereof (within 5 years
             prior to screening).

          4. Patients in whom such active viral infections as HBV, HIV or ATCL or syphilis
             infection cannot be ruled out.

          5. Patients with serum creatinine &gt;1.5 times over upper normal or creatinine clearance
             =&lt;60 mL/min/1.73 m2.

          6. Patients with hemoglobin &lt;8 g/dL.

          7. Patients with platelet count &lt;50,000 /&amp;micro;L.

          8. Patients with T.Bil =&gt;3.0 mg/dL.

          9. Patients with a complication of poorly controlled diabetes, hypertension or heart
             failure.

         10. Patients with a complication of mental disorder requiring treatment.

         11. Patients with serious allergy to contrast media or a history thereof.

         12. Patients with allergy to inactive ingredients of the study drug.

         13. Patients who have received interferon, ribavirin or anti-HCV agents within 12 weeks
             before registration in this study.

         14. When the medical treatment to a primary disease is carried out, Patient who was
             changed the dosage and administration within the 12 weeks before registration.

         15. Patients with a history of drug or alcohol addiction within five years at the time of
             providing written consent or a history of drug or alcohol abuse within the past one
             year.

         16. The patient who received a liver transplant or other organ transplants (a bone marrow
             transplantation is included), and the patient for whom intravenous administration and
             venous access are difficult.

         17. Patients contraindicated for liver biopsy.

         18. Female patients who are pregnant or suspected to be pregnant; or those who desire to
             get pregnant during the study period or those of childbearing potential.

         19. Male patients who do not consent to practice birth control during the clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kiminori Kimura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Komagome Metropolitan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tokyo metropolitan Komagome Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2014</study_first_submitted>
  <study_first_submitted_qc>July 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2014</study_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Komagome Hospital</investigator_affiliation>
    <investigator_full_name>Kiminori Kimura</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Hepatitis C virus, cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

